MPN-RC Monthly Publication

**Title:*Molecular Consequences and Targeting of PPM1D Overexpression in Myeloproliferative Neoplasms***

Authors: Md. Babu Mia, Christoph Schaniel, Cara Clementelli, Sarah Elisabeth Haines, Malgorzata Olszewska, JoAnn Arandela, Sebastian Elghaity-Beckley, Sophie Klingborg, Zinedine Hoque, Ayman Mohammad, Shwetha Hara Sridhar, Brianna Kelly, Xiaoli Wang, Emmanuel Olivier, Alan H Shih, Blake T. Langlais, Allison Cote, Noushin Farnoud, Raajit K. Rampal, Duke Butterfield, Amylou C. Dueck, Min Lu, Kristin G Beaumont, Robert Sebra, John O. Mascarenhas, Eirini P Papapetrou, Ronald Hoffman, Bridget K Marcellino

Full Article

Consortium Member of the Month

Our consortium member of the month for the month of November goes to Heidi Kosiorek from Mayo Clinic!

Heidi Kosiorek, MS

Principal Biostatistician II

Heidi Kosiorek has provided essential biostatistical and clinical trial design expertise to the MPN-RC, working closely with investigators across institutions to advance the Consortium’s clinical research program. Key contributions include development of data infrastructure, clinical trial designs in all trials including novel flexible Bayesian designs, and expert statistical monitoring and analysis of all clinical trials across clinical, laboratory, and patient-reported endpoints. Through this work, Heidi has helped translate complex clinical data into meaningful evidence about treatment benefit, strengthening the Consortium’s scientific rigor while keeping the patient experience central to its research.

Nominated by: Dr. Amylou Dueck

Heidi, thank you so much for all of the phenomenal work you have done for the consortium.

Keep up the great work!

ASH Conference 2025

(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!
(Left to Right: Md. Babu Mia, Noushin Rahnamay, Dr. Bridget Marcellino, and Dr. Raajit Rampal) The Mount Sinai and Memorial Sloan Kettering group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.

ASH Abstracts

Marina Kremyanskaya, MD,PhD

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Full ASH Abstract
John Crispino, PhD,MBA

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Full Ash Abstract
John Mascarenhas, MD

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Full ASH Abstract
Andrew Kuykendall, MD

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Full Ash Abstract
Min Lu, MD,PhD

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Full ASH Abstract
Xiaoli Wang, MD,PhD

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Full Ash Abstract
MD Babu Mia, PhD

Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

Full ASH Abstract